Matritech's NMP22
This article was originally published in The Gray Sheet
Executive Summary
Firm's bladder cancer detection test is sensitive enough to allow urologists to reserve the use of rigid cystoscopy only for patients whose urinary nuclear matrix protein levels are found to be higher than six U/ml with the assay, according to a study of 105 bladder cancer patients by Alberto Del Nero, et al., published in the February edition of the journal European Urology. Using a cutoff of six U/ml, the test demonstrated a sensitivity of 92% (69/75) overall, compared to 50.6% (38/75) for Bion Diagnostics Sciences' BTA stat test and 46.6% (35/75) with urinary cytology
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.